Existing osteoporosis drugs or treatable COVID19

, July 8, 2020 /PRNewswire/ --- -- A high-performance computing platform supported by the European Union has successfully tested the effects of known molecules on the genomic structure of coronaviruses and determined the efficacy of generic drugs that have been registered, according to a recent studythere is a large number of research on potential treatments for COVID-19, including existing drugs that are being trialledSome progress has also been made"The generic drug that has been registered for the treatment of osteoporosis, reloxifen, may be an effective treatment for patients with mild symptomatic infections," the European Commission said in a press releasethe platform, exsCALATE4CoV, brings together supercomputing centres in Germany, Spain and Italy, pharmaceutical companies, large research centers and bio-research institutes throughout EuropeIt uses "a unique combination of high-performance computing capabilities and AI and biological processing." The platform has the computing power of approximately 120 Petaflops to study molecular behavior with a view to identifying effective anti-coronavirus treatments"
(picture:the European Commission press release added: "Supercomputers have been virtually tested on 400,000 molecules7,000 molecules were preselected and further tested "in vitro"Reloxifen became a promising molecule: under the project, it may be effective in preventing the virus from replicating in cells, thus preventing the development of the diseaseAccording to the project partner, Relocifen "has good security and known security." The EXSCALATE4CoV consortium is in discussions with the European Medicines Agency to establish the "fastest human clinical trial pathway"exsCALATE4CoV platform can "complete the selection process that may take many years in a matter of weeks to complete traditional technology." As a first step, it has so far identified six of the 25 different types of coronavirus protein models that have evolvedThe second stage "is to match the digital structure of the coronavirus protein with the available molecular library." In the third and final step, the identified molecules underwent several other bioscreening operations in laboratories in Belgium and Germany to understand how identified molecules interact with viral models and to assess the extent to which they can stop their activity"
in the next phase, the EXSCALATE4CoV platform will expand the current test ingress by taking into account the expanded library of 5 million molecules out of 500 billion molecules in its chemical library(Bio Valley Bioon.com) source: Existing oedis drug shows for the treating COVID-19